Company Overview of MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc., a pharmaceutical company, develops oral and small molecule therapies for adjunctive treatment of Major Depressive Disorder (MDD). It develops Strada, an orally administered therapy that improves the symptoms of depression in patients with MDD. The company was founded in 2007 and is based in Burnaby, Canada.
108-4475 Wayburne Drive
Burnaby, BC BC V5G 4X4
Founded in 2007
Key Executives for MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc. Key Developments
Similar Private Companies By Industry
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
|ABcann Medicinals Inc.||Americas|
Recent Private Companies Transactions
October 6, 2016
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact MSI Methylation Sciences, Inc., please visit www.methylationsciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.